312 related articles for article (PubMed ID: 12071095)
1. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Tasaka K; Ishida A; Chinzei T
Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
[TBL] [Abstract][Full Text] [Related]
2. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
8. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa.
Gerçeker AA; Otük G
Chemotherapy; 1995; 41(6):433-6. PubMed ID: 8529433
[TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I
Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
[TBL] [Abstract][Full Text] [Related]
10. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
Wilhelm CM; Nunes LS; Martins AF; Barth AL
Diagn Microbiol Infect Dis; 2018 Oct; 92(2):152-154. PubMed ID: 29891185
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
Antimicrob Agents Chemother; 1995 Mar; 39(3):731-4. PubMed ID: 7793881
[TBL] [Abstract][Full Text] [Related]
13. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
14. [In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
Anan N; Toba S; Ito A; Nakamura R; Tsuji M
Jpn J Antibiot; 2011 Aug; 64(4):203-16. PubMed ID: 22066345
[TBL] [Abstract][Full Text] [Related]
15. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Hagihara M; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
Tessier F; Quentin C
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
[TBL] [Abstract][Full Text] [Related]
17. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Kakeya H; Yamada K; Nakaie K; Takizawa E; Okada Y; Fujita A; Nakamura Y; Abe J; Hirose A; Kaneko Y; Hino M
Jpn J Antibiot; 2014 Aug; 67(4):241-8. PubMed ID: 25420320
[TBL] [Abstract][Full Text] [Related]
18. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Livermore DM; Yang YJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
Hofer B; Dantier C; Gebhardt K; Desarbre E; Schmitt-Hoffmann A; Page MG
J Antimicrob Chemother; 2013 May; 68(5):1120-9. PubMed ID: 23344577
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
